Mass spectrometry platform could shrink cancer drug discovery cycle to four hours

AI Summary

Researchers at the Purdue Institute for Cancer Research have developed a mass spectrometry platform that could reduce the cancer drug discovery cycle to four hours. This innovation aims to expedite identification of promising therapeutic compounds, potentially transforming cancer treatment development.

Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed to accelerate one of the slowest and most challenging stages of cancer drug discovery: identifying promising compounds that could eventually become new therapies.